ArticleFrontiers in oncology2026
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Methods: SD-EVLPs were purified by differential ultracentrifugation and sucrose density-gradient separation, and characterized by nanoparticle tracking analysis and transmission electron microscopy (TEM). LC-MS cargo profiling and bioinformatic analyses were used to prioritize ferroptosis-related targets and pathways. Cellular uptake and antitumor activities were assessed in lung cancer cells using proliferation, colony formation, migration, and invasion assays. Ferroptosis-associated alterations were evaluated by measuring Fe Results: SD-EVLPs were nanosized vesicles carrying multiple putative bioactive components. Bioinformatics suggested enrichment of ferroptosis-related signals in the PPAR pathway and implicated a candidate FABP4/PPARG/GPX4 axis. SD-EVLPs were efficiently internalized and dose-dependently inhibited proliferation, migration, and invasion, accompanied by increased Fe Discussion: These findings suggest that SD-EVLPs exhibit anti-lung cancer activity, which may be associated with ferroptosis-related changes and modulation of the FABP4/PPARG/GPX4-associated pathway. SD-EVLPs may represent a potential plant-derived nanovesicle platform for lung cancer intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.